Equities analysts forecast that XOMA Co. (NASDAQ:XOMA) will announce sales of $1.23 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for XOMA’s earnings. The highest sales estimate is $2.00 million and the lowest is $450,000.00. XOMA reported sales of $800,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 53.8%. The company is scheduled to report its next quarterly earnings results on Tuesday, May 4th.
On average, analysts expect that XOMA will report full-year sales of $11.60 million for the current financial year, with estimates ranging from $2.30 million to $20.90 million. For the next fiscal year, analysts anticipate that the business will post sales of $14.37 million, with estimates ranging from $2.84 million to $25.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for XOMA.
XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, March 9th. The biotechnology company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.00 by ($0.68). The firm had revenue of $27.58 million for the quarter, compared to analyst estimates of $12.20 million. XOMA had a negative return on equity of 28.83% and a negative net margin of 102.23%.
XOMA traded up $0.60 during trading on Monday, reaching $39.20. 456 shares of the stock were exchanged, compared to its average volume of 56,625. The stock has a market cap of $441.12 million, a P/E ratio of -35.14 and a beta of 1.26. XOMA has a twelve month low of $15.48 and a twelve month high of $46.32. The stock’s 50 day moving average price is $37.85 and its two-hundred day moving average price is $33.85. The company has a debt-to-equity ratio of 0.61, a quick ratio of 4.63 and a current ratio of 4.63.
In other XOMA news, Director Bvf Partners L. P/Il sold 569,797 shares of the company’s stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $38.36, for a total value of $21,857,412.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 9.89% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the company. Cannell Capital LLC bought a new stake in shares of XOMA in the fourth quarter valued at about $506,000. Infrastructure Capital Advisors LLC bought a new stake in shares of XOMA in the fourth quarter valued at about $210,000. BlackRock Inc. boosted its position in shares of XOMA by 6.0% in the fourth quarter. BlackRock Inc. now owns 477,053 shares of the biotechnology company’s stock valued at $21,053,000 after acquiring an additional 26,836 shares during the period. Old Well Partners LLC bought a new stake in shares of XOMA in the fourth quarter valued at about $205,000. Finally, Bank of New York Mellon Corp boosted its position in shares of XOMA by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 62,868 shares of the biotechnology company’s stock valued at $2,775,000 after acquiring an additional 3,126 shares during the period. 57.21% of the stock is owned by institutional investors.
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Further Reading: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.